Search

everythinglearnresearchcommunity

for

Search:↓

Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.

TCDD reduces EGF receptors in the liver, affecting growth and development.

An automated system can predict death risk in thin melanoma by analyzing immune cells.

KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Blocking certain proteins on immune cells may help treat alopecia areata.

Platelet-rich plasma doesn't prevent hair loss from chemotherapy, and mononuclear cells only help against hair loss from one specific chemotherapy drug.

CMV infection increases the risk of GvHD after bone marrow transplants.

Human dermal fibroblasts are the main cells targeted by a virus that can cause a deadly skin cancer, and a certain inhibitor can effectively block this infection.

Tumor proteins can both promote and suppress cancer, depending on the situation.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Thymus-derived Tregs, not peripherally-derived Tregs, primarily regulate type 1 diabetes in the NOD mouse model.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

TRPA1 is crucial for mechanical sensitivity in skin sensory neurons.

TS-13 speeds up hair regrowth after chemotherapy.

Removing the Crif1 gene in mouse skin disrupts skin balance and hair growth.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Expanding CD4+ Tregs can stop hair loss in alopecia areata.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Krt15+ cells in the mouse intestine resist radiation and can start tumors.

Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.

CGRP may help protect hair follicles from immune system attacks, potentially slowing hair loss.

Activating certain hair follicle cells could prevent hair loss from cancer treatments.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

Dyclonine can effectively reduce skin issues by inhibiting the TRPV3 channel.

Tsc2-deficient stem cells can help understand and treat TSC-related tumors.

Using a combination of specific cell cycle regulators is better for safely keeping hair root cells alive indefinitely compared to cancer-related methods.